In breast cancer patients, inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), which are fundamental drivers of cell cycle progression downstream of oncogenic signaling pathways, induces significant anti-tumor immune responses [63]. This evidence concerns the gene CDK4 and breast carcinoma.